Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.
What happened
FDA inspected Denison's Lincoln, RI drug manufacturing facility from January 5 to February 9, 2023 and found inadequate investigations into lubricant contamination, foul-odor/microbial failures, and water-system excursions; it also found no diethylene glycol/ethylene glycol identity testing for glycerin and propylene glycol and unvalidated rapid microbial test methods. FDA also reviewed labels and websites for Colic Calm, Colic Calm +, and Nauzene Kids and found them to be unapproved new drugs. After FDA recommended removing batches made during lubricant use, the company recalled four products in May 2023.
What FDA found
The company did not thoroughly investigate batch failures and complaints, including lubricant contamination, foul-odor batches with too-numerous-to-count yeast/mold, and water-system microbial excursions.
21 CFR 211.192The company did not perform identity testing for every lot of glycerin and propylene glycol to detect diethylene glycol (DEG) and ethylene glycol (EG).
21 CFR 211.84(d)(1)The company used an unvalidated rapid microbiological test method and released lots despite failing results.
21 CFR 211.165(e)The company marketed Colic Calm, Colic Calm +, and Nauzene Kids as drugs without FDA-approved applications.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
What FDA wants
FDA asks Denison to correct the violations promptly and provide comprehensive independent assessments and remediation plans for investigations, corrective and preventive action (CAPA), the water system, component testing, and laboratory methods, plus a risk assessment for DEG/EG and recall actions for affected lots; no response deadline is stated in the provided text.
Who should pay attention
- companies using Denison as a contract manufacturer
- retailers and distributors of Colic Calm, Nauzene Kids, or recalled products
- drugmakers that use glycerin or propylene glycol
This is a summary. Read the original letter on fda.gov.